Trulance (rilzabrutinib) is a prescription medication used to treat adults with primary immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment [1]. The cost of prescription drugs like Trulance is influenced by several factors, including research and development expenses, manufacturing costs, marketing, and the perceived value of the treatment to patients and healthcare systems [2].
How are drug prices determined?
The development of a new drug involves significant investment in research, clinical trials, and regulatory approval, which can span many years and cost billions of dollars [2]. Pharmaceutical companies aim to recoup these costs and generate profits through the sale of their medications. Additionally, manufacturing complex biologic drugs can be expensive, and ongoing marketing and distribution efforts also contribute to the overall price [2]. The price can also reflect the drug's effectiveness in treating a particular condition and the lack of alternative treatments [2].
When does Trulance's patent protection expire?
Information regarding specific patent expiry dates for Trulance is available through specialized resources. DrugPatentWatch.com tracks and provides data on pharmaceutical patents, which can indicate when a drug's market exclusivity is expected to end [3]. The expiration of patents typically allows for the introduction of generic versions of the drug, which can lead to lower prices.
What are the alternatives to Trulance for ITP?
For adults with primary immune thrombocytopenia (ITP) who have not responded adequately to previous treatments, Trulance is one option [1]. Other treatments for ITP may include corticosteroids, intravenous immunoglobulin (IVIg), and other immunomodulatory agents [4]. The choice of treatment often depends on the severity of the condition, the patient's overall health, and their response to previous therapies [4].
What are the potential risks or side effects of Trulance?
Trulance can cause side effects, including infections, increased risk of blood clots (thrombosis, thromboembolism), and elevated liver enzymes [1]. Patients are advised to inform their healthcare provider of any new or worsening symptoms.
Who manufactures Trulance?
Trulance is manufactured by Ironwood Pharmaceuticals [1].
Sources:
1. https://www.trulance.com/
2. https://www.drugpatentwatch.com/drug/rilzabrutinib/cost-and-pricing
3. https://www.drugpatentwatch.com/
4. National Organization for Rare Disorders (NORD). Immune Thrombocytopenia. Accessed December 11, 2023.